Search results for "Injection"

showing 10 items of 920 documents

Dose-dependent metabolism and hepatic distribution of phenprocoumon in rats

1988

The dose-dependency of phenprocoumon disposition was determined in rats by iv administration of 0.1 and 1.0 mg/kg doses to separate groups of animals. The intrinsic clearance (unbound clearance) was 33% lower in the animals given 1.0 mg/kg dose than in the animals given 0.1 mg/kg dose. The apparent unbound volume of distribution was 55% lower and the elimination rate constant 54% higher in the high dose group than in the lower dose group. Binding of phenprocoumon to liver showed saturability with a two- to threefold higher apparent unbound fraction of phenprocoumon in liver in animals given the high dose in comparison to animals given the low dose.

Malemedicine.medical_specialtymedicine.drug_classDose dependencePhenprocoumonPharmacokineticsElimination rate constantInternal medicinemedicineAnimalsDistribution (pharmacology)Tissue DistributionPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsVolume of distributionDose-Response Relationship DrugChemistryAnticoagulantRats Inbred Strains4-HydroxycoumarinsMetabolismRatsEndocrinologyLiverInjections IntravenousPhenprocoumonCarrier Proteinsmedicine.drugJournal of Pharmacokinetics and Biopharmaceutics
researchProduct

‘Not at all what I had expected’: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study

2021

Background: Extended-release naltrexone (XR-NTX), an opioid antagonist, has demonstrated equal treatment outcomes, in terms of safety, opioid use, and retention, to the recommended OMT medication buprenorphine. However, premature discontinuation of XR-NTX treatment is still common and poorly understood. Research on patient experiences of XR-NTX treatment is limited. We sought to explore participants' experiences with discontinuation of treatment with XR-NTX, particularly motivation for XR-NTX, experiences of initiation and treatment, and rationale for leaving treatment. Methods: We conducted qualitative, semi-structured interviews with participants from a clinical trial of XR-NTX. The study…

Malemedicine.medical_specialtymedicine.drug_classNarcotic Antagonistsmedia_common.quotation_subjectMedicine (miscellaneous)Injections IntramuscularNaltrexonemedicineHumansVDP::Medisinske Fag: 700PsychiatryQualitative Researchmedia_commonbusiness.industryClinical Studies as TopicAbstinenceOpioid-Related DisordersNaltrexoneBuprenorphineDiscontinuationAnalgesics OpioidClinical trialPsychiatry and Mental healthClinical PsychologyVDP::Medisinske Fag: 700::Helsefag: 800Delayed-Action PreparationsFemalePshychiatric Mental HealthThematic analysisbusinesshuman activitiesOpioid antagonistQualitative researchmedicine.drugBuprenorphine
researchProduct

Differences in the composition of inflammatory cell infiltrate in lens-induced uveitis under therapy with allopurinol or steroids.

2001

Purpose The aim of this study was to compare the qualitative changes in the composition of inflammatory cell infiltrate in lens-induced uveitis (LIU) under treatment with allopurinol (Allo), methylprednisolone (Pred) or the two drugs combined (Allo/Pred). Methods Twenty male Wistar rats were sensitized with lens proteins for eight weeks. Intravenous (IV) therapy was started after anterior capsule disruption in one eye of each animal. Five rats were randomly assigned to each of the four groups: controls, Allo (50 mg/kg bw), Pred (7.5 mg/kg bw) and Allo/Pred (50 mg/7.5 mg per kg bw). Eyes were enucleated 24 hours later and fixed in paraformaldehyde/glutaraldehyde. Sections at three levels wer…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentAllopurinolAllopurinolMethylprednisoloneGiemsa stainLens proteinUveitis03 medical and health scienceschemistry.chemical_compoundLeukocyte Count0302 clinical medicineInternal medicinemedicineLeukocytesAnimalsRats WistarParaformaldehydeGlucocorticoidsChemotherapybusiness.industryGeneral MedicineFree Radical Scavengersmedicine.diseaseCrystallinsRatsOphthalmologyDisease Models AnimalEndocrinologychemistryMethylprednisoloneInjections Intravenous030221 ophthalmology & optometryCorticosteroidDrug Therapy Combinationbusiness030217 neurology & neurosurgeryUveitismedicine.drugEuropean journal of ophthalmology
researchProduct

Sulpiride has an antiaggressive effect in mice without markedly depressing motor activity

1991

The atypical neuroleptic, sulpiride is a selective D2 antagonist, having a preferential action on mesolimbic regions. The effects of acute and chronic treatment with sulpiride on aggressive behaviour in male mice were studied using an ethologically based analysis. It was hypothesized that sulpiride would diminish "threat" and "attack" but would not produce marked "immobility", because of the mesolimbic effect referred to above. Isolated albino male mice (experimental animals) were confronted by "standard opponents". Acutely-treated experimental animals received an intraperitoneal injection of sulpiride (20, 50 or 100 mg/kg) 30 min before testing. Chronically-treated animals received sulpiri…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentIntraperitoneal injectionMice Inbred StrainsMotor ActivityAnxiolyticDopamine agonistMiceCellular and Molecular NeuroscienceReference ValuesInternal medicinemedicineAnimalsMotor activitySocial BehaviorPharmacologyDose-Response Relationship DrugDopaminergicAntagonistGroomingAggressionDose–response relationshipEndocrinologyExploratory BehaviorSulpiridePsychologySulpiridemedicine.drugNeuropharmacology
researchProduct

EFFECTS OF 4-AMINOPYRIDINE ON ACETYLCHOLINE OUTPUT FROM THE CEREBRAL CORTEX OF THE RAT in vivo

1982

Abstract 1 The effects of 4-aminopyridine (4AP) on the output of acetylcholine (ACh) from the cerebral cortex were investigated in unanaesthetized freely moving rats and in anaesthetized rats by means of the `cup technique'. ACh was determined by bioassay on the dorsal muscle of the leech. 2 In unanaesthetized rats intraperitoneal injection of 4AP (3 mg/kg) had no effect on the cortical output of ACh. 3 After injection of morphine (10 mg/kg s.c.), which depressed the spontaneous output of ACh, 4AP increased the cortical output to a level significantly higher than that determined before morphine injection. 4 In rats anaesthetized with either urethane or pentobarbitone, drugs known to decreas…

Malemedicine.medical_specialtymedicine.medical_treatmentIntraperitoneal injectionAminopyridinesBlood PressureInternal medicinemedicinePrazosinAnimalsAnesthesia4-AminopyridineCerebral CortexPharmacologyMorphineChemistry4-AminopyridineRats Inbred StrainsVagotomyAcetylcholineRatsmedicine.anatomical_structureEndocrinologyCerebral cortexNeuromuscular Depolarizing AgentsAnesthesiaPapersMorphineExcitatory postsynaptic potentialAcetylcholinemedicine.drugBritish Journal of Pharmacology
researchProduct

Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases.

1994

A multicenter, randomized Phase 2 study that compared patients, affected by colorectal liver metastases, who received intrahepatic arterial infusion with two different schedules of cisplatin, bolusvs. continuous infusion, and systemic 5-fluorouracil. PURPOSE: The aim of this study was to validate results of a previous Phase 2 trial on bolus cisplatin intrahepatic arterial infusion, which reported a 47 percent response rate and a 32 percent 4-year survival rate for Gennari's Stage 2 patients, with a high rate of neurologic, gastrointestinal, and hematologic toxicity. METHODS: One hundred nine patients were randomized in a Phase 2 study to receive cisplatin intrahepatic arterial infusion (24 …

Malemedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchGastroenterologyBolus (medicine)Hepatic arterial infusionHepatic ArteryInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions Intra-ArterialInfusions IntravenousSurvival rateCisplatinChemotherapybusiness.industryLiver NeoplasmsGastroenterologyGeneral MedicineMiddle AgedSurvival RateInjections Intra-ArterialFluorouracilAnesthesiaToxicityFemaleFluorouracilCisplatinbusinessColorectal Neoplasmsmedicine.drugDiseases of the colon and rectum
researchProduct

Vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis.

2011

The aim of this study was to define a two-compartments pharmacokinetic model and to estimate the pharmacokinetic parameters of IP administered vancomycin in patients with continuous ambulatory peritoneal dialysis (CAPD) associated peritonitis. Ten patients with peritoneal dialysis treatment and peritonitis were prospectively enrolled in the study. The empiric treatment is: vancomycin 2 g every 5-7 days and ceftazidime 1500 mg per exchange, once daily. Pharmacokinetic modeling and parameter calculations were carried out using the nonlinear regression. The mean peritoneal concentration 10 min after the first peritoneal exchange of vancomycin free dialysis liquid was 9.5±7.3 μg/ml, showing tha…

Malemedicine.medical_specialtymedicine.medical_treatmentUrologyPharmaceutical SciencePeritonitisPeritonitisCeftazidimePeritoneal dialysisPharmacokineticsPeritoneal Dialysis Continuous AmbulatoryVancomycinmedicineHumansDialysisAntibacterial agentAgedbusiness.industryContinuous ambulatory peritoneal dialysisMiddle Agedmedicine.diseaseSurgeryAnti-Bacterial AgentsAmbulatoryVancomycinFemalebusinessInjections Intraperitonealmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

A comparison of the effects of Methylprednisolone Acetate, Sodium Hyaluronate and Tenoxicam in the treatment of non-reducing disc displacement of the…

2018

Background This clinical study aimed to radiologically and clinically compare the effect of intra-articular injection of methylprednisolone, sodium hyaluronate or tenoxicam following arthrocentesis with that of arthrocentesis alone in patients with non-reducing disc displacement. Material and Methods A total of 44 patients radiographically diagnosed with non-reducing disc displacement of the temporomandibular joint (TMJ) were randomly divided into four treatment groups, as follows: Group 1, arthrocentesis alone; Group 2, arthrocentesis plus methylprednisolone acetate; Group 3, arthrocentesis plus sodium hyaluronate; Group 4, arthrocentesis plus tenoxicam. Maximum mouth opening (MMO), latera…

Malemedicine.medical_treatmentSodium hyaluronateAnti-Inflammatory AgentsInjections Intra-Articular03 medical and health scienceschemistry.chemical_compoundPiroxicam0302 clinical medicineTenoxicamMedicineHumansSingle-Blind MethodProspective StudiesHyaluronic AcidGeneral Dentistrymedicine.diagnostic_testViscosupplementsbusiness.industryResearchAnti-Inflammatory Agents Non-SteroidalArthrocentesisMagnetic resonance imaging030206 dentistryMethylprednisolone acetateTemporomandibular Joint Disorders:CIENCIAS MÉDICAS [UNESCO]Combined Modality TherapyTemporomandibular jointMethylprednisolone Acetatemedicine.anatomical_structureOtorhinolaryngologychemistryEffusionMethylprednisolone030220 oncology & carcinogenesisAnesthesiaUNESCO::CIENCIAS MÉDICASSurgeryFemaleOral Surgerybusinessmedicine.drugArthrocentesisMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

The comparison of knee osteoarthritis treatment with single-dose bone marrow-derived mononuclear cells vs. hyaluronic acid injections

2017

Objective: The aim of this study was to compare treatment methods of the knee joint degenerative osteoarthritis, using autologous bone marrow-derived mononuclear cells and hyaluronic acid injections and observe prevalence of adverse effects in both groups. Materials and methods: A prospective randomized controlled clinical trial was carried out. The analysis of pain and changes in osteoarthritis symptoms after a single intra-articular bone marrow-derived mononuclear cell injection into the knee joint in the Kellgren– Lawrence stage II–III osteoarthritis during the 12-month period were performed. The results were compared with the control group treated routinely by hyaluronic acid injections…

Malemusculoskeletal diseasesmedicine.medical_specialtySodium hyaluronateKnee osteoarthritis; Bone marrow mononuclear cells; CartilageUrologyOsteoarthritisKnee JointPeripheral blood mononuclear cellMonocytesInjections Intra-Articular03 medical and health scienceschemistry.chemical_compound0302 clinical medicineStatistical significanceHyaluronic acidHumansMedicineHyaluronic AcidAdverse effectAgedBone Marrow TransplantationMedicine(all)030203 arthritis & rheumatology030222 orthopedicslcsh:R5-920business.industryMiddle AgedOsteoarthritis Kneemedicine.diseaseTreatment Outcomemedicine.anatomical_structureCartilagechemistryAutomotive EngineeringBone marrow mononuclear cellsFemaleBone marrowKnee osteoarthritisbusinesslcsh:Medicine (General)Medicina
researchProduct

Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register

2021

AbstractThe current study aims to compare injectable and oral first-line disease-modifying therapies (DMTs) for time to first relapse, time to confirmed disability progression (CDP), and time to discontinuation using a cohort of relapsing remitting multiple sclerosis (RRMS) patients, with data extracted from the Italian MS Register. This multicenter, observational, retrospectively acquired, and propensity-adjusted cohort study utilized RRMS-naïve patients from the Italian MS Register who started either injectable or oral first-line DMTs between January 1, 2010, and December 31, 2017, to evaluate the impact on disability outcomes in patients. Enrolled patients were divided into two groups, n…

Maleoral DMTsoral DMTAdministration OralDiseaseRelapsing-RemittingCohort Studies0302 clinical medicineImmunologicinjectable DMTPharmacology (medical)030212 general & internal medicineRegistriesSubcutaneousMiddle AgedItalyEDSS score; injectable DMTs; Multiple sclerosis; oral DMTs; real-world setting; Adjuvants Immunologic; Administration Oral; Adult; Cohort Studies; Female; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Injections Subcutaneous; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; RegistriesAdministrationCohortSettore MED/26 - NeurologiaOriginal ArticleFemaleNeurosurgeryCohort studyOralAdultmedicine.medical_specialtyEDSS scoreInjections SubcutaneousLower riskInjectionsMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicInternal medicinereal-world settingmedicineHumansImmunologic FactorsMultiple sclerosiAdjuvantsinjectable DMTsRetrospective StudiesPharmacologybusiness.industryMultiple sclerosisGlatiramer AcetateInterferon-betamedicine.diseaseDiscontinuationObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up Studies
researchProduct